LIFE Fundamental Analysis - LIFECARE ASA

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to LIFE. LIFE was compared to 63 industry peers in the Health Care Equipment & Supplies industry. The financial health of LIFE is average, but there are quite some concerns on its profitability. LIFE is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

LIFE had negative earnings in the past year.

LIFE had a negative operating cash flow in the past year.

LIFE had negative earnings in each of the past 5 years.

In the past 5 years LIFE always reported negative operating cash flow.

1.2 Ratios

LIFE has a Return On Assets of -93.35%. This is amonst the worse of the industry: LIFE underperforms 95.24% of its industry peers.

LIFE's Return On Equity of -124.42% is on the low side compared to the rest of the industry. LIFE is outperformed by 85.71% of its industry peers.

		Industry Rank	Sector Rank
ROA	-93.35%
ROE	-124.42%
ROIC	N/A

ROA(3y)-42.61%

ROA(5y)-38.99%

ROE(3y)-60.35%

ROE(5y)-53.22%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LIFE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, LIFE has more shares outstanding

Compared to 5 years ago, LIFE has less shares outstanding

The debt/assets ratio for LIFE has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -1.38, we must say that LIFE is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -1.38, LIFE is doing worse than 79.37% of the companies in the same industry.

LIFE has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.

LIFE has a better Debt to Equity ratio (0.12) than 73.02% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Altman-Z	-1.38

ROIC/WACCN/A

WACC7.95%

2.3 Liquidity

LIFE has a Current Ratio of 3.34. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.

LIFE has a Current ratio of 3.34. This is amongst the best in the industry. LIFE outperforms 87.30% of its industry peers.

A Quick Ratio of 3.34 indicates that LIFE has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.34, LIFE belongs to the top of the industry, outperforming 92.06% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.34
Quick Ratio	3.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for LIFE have decreased strongly by -40.55% in the last year.

LIFE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.10%.

Measured over the past years, LIFE shows a very strong growth in Revenue. The Revenue has been growing by 36.13% on average per year.

EPS 1Y (TTM)-40.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.33%

Revenue 1Y (TTM)-26.1%

Revenue growth 3Y82.19%

Revenue growth 5Y36.13%

Sales Q2Q%-99.89%

3.2 Future

The Earnings Per Share is expected to grow by 8.88% on average over the next years. This is quite good.

LIFE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.02% yearly.

EPS Next Y8.12%

EPS Next 2Y10.07%

EPS Next 3Y8.88%

EPS Next 5YN/A

Revenue Next Year-75%

Revenue Next 2Y15.47%

Revenue Next 3Y53.03%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LIFE. In the last year negative earnings were reported.

Also next year LIFE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.07%

EPS Next 3Y8.88%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LIFE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LIFECARE ASA

OSL:LIFE (12/8/2025, 7:00:00 PM)

5.54

+0.34 (+6.54%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)08-27 2024-08-27/bmo

Earnings (Next)N/A N/A

Inst Owners7.56%

Inst Owner ChangeN/A

Ins Owners7.41%

Ins Owner ChangeN/A

Market Cap105.59M

Revenue(TTM)2.83M

Net Income(TTM)-73.93M

AnalystsN/A

Price Target36.72 (562.82%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)4.23%

EPS NY rev (3m)4.23%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-50%

Revenue NY rev (3m)-50%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	37.3
P/FCF	N/A
P/OCF	N/A
P/B	1.78
P/tB	2.23
EV/EBITDA	N/A

EPS(TTM)-16.64

EYN/A

EPS(NY)-3.76

Fwd EYN/A

FCF(TTM)-4.2

FCFYN/A

OCF(TTM)-3.63

OCFYN/A

SpS0.15

BVpS3.12

TBVpS2.48

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-93.35%
ROE	-124.42%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-42.61%

ROA(5y)-38.99%

ROE(3y)-60.35%

ROE(5y)-53.22%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	192.06%
Cap/Sales	386.15%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.34
Quick Ratio	3.34
Altman-Z	-1.38

F-Score1

WACC7.95%

ROIC/WACCN/A

Cap/Depr(3y)168.09%

Cap/Depr(5y)N/A

Cap/Sales(3y)55.69%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-40.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.33%

EPS Next Y8.12%

EPS Next 2Y10.07%

EPS Next 3Y8.88%

EPS Next 5YN/A

Revenue 1Y (TTM)-26.1%

Revenue growth 3Y82.19%

Revenue growth 5Y36.13%

Sales Q2Q%-99.89%

Revenue Next Year-75%

Revenue Next 2Y15.47%

Revenue Next 3Y53.03%

Revenue Next 5YN/A

EBIT growth 1Y-139.85%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year5.41%

EBIT Next 3Y6.74%

EBIT Next 5YN/A

FCF growth 1Y-189.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-164.06%

OCF growth 3YN/A

OCF growth 5YN/A

LIFECARE ASA / LIFE.OL FAQ

What is the ChartMill fundamental rating of LIFECARE ASA (LIFE.OL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LIFE.OL.

What is the valuation status for LIFE stock?

ChartMill assigns a valuation rating of 0 / 10 to LIFECARE ASA (LIFE.OL). This can be considered as Overvalued.

How profitable is LIFECARE ASA (LIFE.OL) stock?

LIFECARE ASA (LIFE.OL) has a profitability rating of 0 / 10.

Can you provide the financial health for LIFE stock?

The financial health rating of LIFECARE ASA (LIFE.OL) is 5 / 10.

LIFECARE ASA (LIFE.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

LIFECARE ASA / LIFE.OL FAQ

What is the ChartMill fundamental rating of LIFECARE ASA (LIFE.OL) stock?

What is the valuation status for LIFE stock?

How profitable is LIFECARE ASA (LIFE.OL) stock?

Can you provide the financial health for LIFE stock?